Daniel Artenstein

Papers

Total Citations

H-Index

About

Dr. Daniel Artenstein is a urologic oncologist whose research focuses on optimizing treatment outcomes for prostate cancer patients, particularly through the integration of neoadjuvant hormonal therapy with radical prostatectomy. His most-cited work, a 2020 study on neoadjuvant leuprolide therapy, examines the long-term effects of this approach on health-related quality of life, a critical yet often underexplored dimension of cancer care. This contribution underscores his commitment to balancing oncologic efficacy with patient-centered outcomes, addressing how preoperative hormonal manipulation impacts postoperative recovery, urinary function, and psychological well-being. While his citation count reflects a growing recognition of this niche area, his work is notable for its emphasis on longitudinal, patient-reported data—a methodology that is increasingly valued in surgical oncology. Dr. Artenstein’s research bridges the gap between aggressive cancer treatment and survivorship, offering insights that help clinicians tailor therapies to individual patient priorities. His findings contribute to the broader conversation on multimodal management of localized prostate cancer, highlighting the need for personalized strategies that consider both tumor control and quality of life.